Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (19,116)	$ (4,832)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	705	311
Research and development expensed - license acquired	0	192
Change in fair value of convertible notes payable		0
Change in fair value of warrant liability	1,533	(654)
Amortization of debt discount	986	0
Changes in operating assets and liabilities from continuing operations:
Prepaid expenses and other current assets	(777)	(648)
Accounts payable	(259)	2,486
Accrued expenses	(199)	(428)
Licenses payable	5,875	(2,850)
Net cash used in operating activities	(11,252)	(6,423)
Cash flows from financing activities:
Payment of convertible note	(5,167)	0
Proceeds from issuance of common stock, net of issuance costs	33,481	0
Proceeds from issuance of common stock, pursuant to Securities Purchase Agreement, net of issuance costs	0	8,850
Proceeds from exercise of warrants	5,868	0
Proceeds from exercise of options	65	0
Proceeds from sales of common stock under ESPP	30	0
Net cash provided by financing activities	34,277	8,850
Cash flows from discontinued operations:
Net increase in cash	23,025	2,427
Cash, beginning of period	15,662	10,261
Cash, end of period	38,687	12,658
Supplemental disclosure of cash flow information:
Cash paid for interest	4	4
Cash paid for income taxes	0	0
Non-cash investing and financing activities:
Reclass of warrant liabilities related to Series A warrants exercised for cash	1,155	0
Right-of-use assets obtained in exchange for operating lease liabilities	$ 74	$ 0